Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
C E Geyer Jr,J E Garber,R D Gelber,G Yothers,M Taboada,L Ross,P Rastogi,K Cui,A Arahmani,G Aktan,A C Armstrong,M Arnedos,J Balmaña,J Bergh,J Bliss,S Delaloge,S M Domchek,A Eisen,F Elsafy,L E Fein,A Fielding,J M Ford,S Friedman,K A Gelmon,L Gianni,M Gnant,S J Hollingsworth,S-A Im,A Jager,Ó Þ Jóhannsson,S R Lakhani,W Janni,B Linderholm,T-W Liu,N Loman,L Korde,S Loibl,P C Lucas,F Marmé,E Martinez de Dueñas,R McConnell,K-A Phillips,M Piccart,G Rossi,R Schmutzler,E Senkus,Z Shao,P Sharma,C F Singer,T Španić,E Stickeler,M Toi,T A Traina,G Viale,G Zoppoli,Y H Park,R Yerushalmi,H Yang,D Pang,K H Jung,A Mailliez,Z Fan,I Tennevet,J Zhang,T Nagy,G S Sonke,Q Sun,M Parton,M A Colleoni,M Schmidt,A M Brufsky,W Razaq,B Kaufman,D Cameron,C Campbell,A N J Tutt,OlympiA Clinical Trial Steering Committee and Investigators
DOI: https://doi.org/10.1016/j.annonc.2022.09.159
Abstract:Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. Patients and methods: One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. Results: With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. Conclusion: With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.